Limits...
The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents.

Liu WM, Stimson LA, Joel SP - Br. J. Cancer (2002)

Bottom Line: Proliferation assays showed STI571 to be an effective cytotoxic agent in chronic myeloid leukaemia-derived cell lines (IC(50) on day 5 of 4.6 microg ml(-1) and 3.4 microg ml(-1) for K562 and KU812 respectively) and in leukaemic blast cells (per cent viability on day 3 at 4 microg ml(-1): 55.5+/-8.7 vs 96.4+/-3.7%).STI571 also appeared to specifically target bcr-abl expressing cells, as results from colony forming assays using the surviving cell fraction from STI571-treated peripheral CD34(+) chronic myeloid leukaemia blast cells, indicated a reduction in the expansion of colonies of myeloid lineage, but no effect on normal colony formation.Our data also showed synergy between STI571 and other anti-leukaemic agents; as an example, there were significant increases in per cent cell kill in cell lines cultured with both STI571 and etoposide compared to the two alone (per cent cell kill on day 3: 73.7+/-11.3 vs 44.5+/-8.7 and 17.8+/-7.0% in cultures with STI571 and etoposide alone respectively; P<0.001).

View Article: PubMed Central - PubMed

Affiliation: Barry Reed Oncology Laboratory, 4th Floor, 38 Little Britain, St. Bartholomew's Hospital, West Smithfield, London EC1A 7BE, UK. w.a.i.liu@qmul.ac.uk

Show MeSH

Related in: MedlinePlus

Effect of 5 μg ml-1 STI571 on cell cycle distribution over 5-days in K562 cells. Points represent the means and s.d. of four separate experiments.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2375377&req=5

fig2: Effect of 5 μg ml-1 STI571 on cell cycle distribution over 5-days in K562 cells. Points represent the means and s.d. of four separate experiments.

Mentions: Flow cytometric analysis showed an increased number of cells undergoing apoptosis in cultures with STI571, with concomitant reductions in the other phases of the cell cycle. This was most clearly demonstrated in K562 cells treated with 5 μg ml−1 STI571 (Figure 2Figure 2


The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents.

Liu WM, Stimson LA, Joel SP - Br. J. Cancer (2002)

Effect of 5 μg ml-1 STI571 on cell cycle distribution over 5-days in K562 cells. Points represent the means and s.d. of four separate experiments.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2375377&req=5

fig2: Effect of 5 μg ml-1 STI571 on cell cycle distribution over 5-days in K562 cells. Points represent the means and s.d. of four separate experiments.
Mentions: Flow cytometric analysis showed an increased number of cells undergoing apoptosis in cultures with STI571, with concomitant reductions in the other phases of the cell cycle. This was most clearly demonstrated in K562 cells treated with 5 μg ml−1 STI571 (Figure 2Figure 2

Bottom Line: Proliferation assays showed STI571 to be an effective cytotoxic agent in chronic myeloid leukaemia-derived cell lines (IC(50) on day 5 of 4.6 microg ml(-1) and 3.4 microg ml(-1) for K562 and KU812 respectively) and in leukaemic blast cells (per cent viability on day 3 at 4 microg ml(-1): 55.5+/-8.7 vs 96.4+/-3.7%).STI571 also appeared to specifically target bcr-abl expressing cells, as results from colony forming assays using the surviving cell fraction from STI571-treated peripheral CD34(+) chronic myeloid leukaemia blast cells, indicated a reduction in the expansion of colonies of myeloid lineage, but no effect on normal colony formation.Our data also showed synergy between STI571 and other anti-leukaemic agents; as an example, there were significant increases in per cent cell kill in cell lines cultured with both STI571 and etoposide compared to the two alone (per cent cell kill on day 3: 73.7+/-11.3 vs 44.5+/-8.7 and 17.8+/-7.0% in cultures with STI571 and etoposide alone respectively; P<0.001).

View Article: PubMed Central - PubMed

Affiliation: Barry Reed Oncology Laboratory, 4th Floor, 38 Little Britain, St. Bartholomew's Hospital, West Smithfield, London EC1A 7BE, UK. w.a.i.liu@qmul.ac.uk

Show MeSH
Related in: MedlinePlus